Concerto Biosciences Announces Strategic Business Development Hire

Concerto Biosciences Announces Strategic Business Development Hire

Didier Vingadassalom, Ph.D., to Generate New Partnerships as Concerto’s Senior Director, Business enterprise Development and Company’s Initial Worker Dedicated to Enterprise Development

CAMBRIDGE, Mass., February 06, 2023–(Business WIRE)–Concerto Biosciences, a biotechnology firm creating microbial communities that restore wellness to our bodies and our setting, declared now that it has appointed Didier Vingadassalom, Ph.D., MBA, as Senior Director, Business enterprise Advancement. Vingadassalom will emphasis on making partnerships across biotech and pharma that leverage Concerto’s rigorous discovery system. He will be liable for maturing the team’s company progress infrastructure, assessing co-discovery and co-development partnership chances, and helping prioritize internal technological know-how improvement instructions from a business growth standpoint.

With far more than 15 yrs of working experience in pharmaceutical and biotech drug discovery and enterprise growth, Vingadassalom has assembled cross-useful groups to assess partnering chances, guided effective R&D collaboration negotiations, and created and applied alliance administration best procedures to improve the good results, price and efficiency of partnered programs.

“Didier has both of those a deep scientific history and yrs of organization development experience— a powerful blend and a great match for Concerto as our very first senior director of small business development,” claimed Cheri Ackerman, CEO of Concerto. “Our science group by now excels at swiftly discovering optimized microbial products and solutions with our kChip platform, and Didier will help us place that one of a kind functionality at pressing, substantial-value opportunities in collaboration with our partners.”

Prior to joining Concerto Biosciences, Vingadassalom was senior director, small business advancement and head of alliance management, SQZ Biotechnologies. Vingadassalom also spent additional than a 10 years at Sanofi Pasteur in different roles, including director of exterior innovation, major scientific lookup and evaluation of partnering prospects for R&D, and deputy director of discovery research on the company’s new pertussis vaccine program. In his early decades at Sanofi Pasteur, Vingadassalom assisted progress an investigational periodontal condition vaccine and monoclonal antibody system.

“Concerto is led by a devoted, pro team that has a eyesight to transform how the microbial planet is viewed and translated into products and solutions,” Vingadassalom explained. “The organization is at a pivotal moment in its evolution. I glimpse forward to driving firm advancement and main developments as a member of the Concerto ensemble.”

A native of Guadeloupe, Vingadassalom gained his Master of Science in biochemistry, Learn of Highly developed Experiments in microbiology, and doctorate in biochemistry and microbiology from Pierre and Marie Curie University in Paris. He retains a Grasp of Business enterprise Administration from Northeastern College in Boston.

Adhering to a $23 million Sequence A fundraise, Concerto is at the moment diversifying its foundational discovery system, kChip, throughout industries as diverse as healthcare, agriculture, and home goods.

About Concerto Biosciences

Concerto Biosciences rebuilds microbial communities in, on, and all around us to mend our bodies and our earth. Goods that rebuild microbial communities do not nevertheless exist since no 1 can map the extensive inter-species conversation networks dependable for community actions. Concerto’s founders invented kChip, the initially-ever ultra-higher-throughput system to experimentally measure millions of microbial interactions. Utilizing kChip knowledge, Concerto can map interaction networks that reveal a new class of goods it calls “ensembles”—combinations of microbes that operate in concert to shepherd damaged microbial communities to overall health. Due to the fact launching Concerto in 2020, the team has assembled a human skin microbe biobank, calculated >6 million interactions with kChip, and identified an ensemble that corrects the microbial deficiency underlying atopic dermatitis. The options are huge: Concerto aims to become the premier inventor of ensembles across drugs and agriculture, reinventing humanity’s romantic relationship with microbes.

To study much more about Concerto Biosciences, stop by

View supply edition on


Robyn Jackson
[email protected]